In addition, Cheng et al. found that H3K18 la promotes high expression of Rubcnl in CRC by positively regulating its transcription, which supported cancer cell proliferation and survival, resulting in poor CRC prognosis and reduced bevacizumab efficacy [179]. The gene discussed is RUBCNL; the disease is colorectal carcinoma.